loading
前日終値:
$0.8936
開ける:
$0.8913
24時間の取引高:
736.00K
Relative Volume:
0.25
時価総額:
$39.52M
収益:
-
当期純損益:
$-31.11M
株価収益率:
-0.3805
EPS:
-2.38
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
+1.75%
1か月 パフォーマンス:
-13.76%
6か月 パフォーマンス:
-72.39%
1年 パフォーマンス:
-78.39%
1日の値動き範囲:
Value
$0.866
$0.9282
1週間の範囲:
Value
$0.80
$0.9282
52週間の値動き範囲:
Value
$0.80
$6.00

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
名前
Tempest Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
415-798-8589
Name
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Name
職員
17
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
TPST's Discussions on Twitter

TPST を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TPST 0.9055 39.52M 0 -31.11M -28.18M -2.38
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Tempest Therapeutics Inc (TPST) 最新ニュース

pulisher
Nov 18, 2024

William Blair Has Negative Estimate for TPST FY2024 Earnings - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Research Analysts Offer Predictions for TPST FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

500: Something went wrong - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Nov 15, 2024
pulisher
Nov 13, 2024

Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Tempest Therapeutics (TPST) Stock Jumps 83% On FDA Phase 3 Trial News - Barchart

Nov 12, 2024
pulisher
Oct 30, 2024

TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK

Oct 30, 2024
pulisher
Oct 16, 2024

Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex

Oct 15, 2024
pulisher
Oct 14, 2024

TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News

Oct 14, 2024
pulisher
Oct 11, 2024

Tempest Therapeutics Inc [TPST] Stock trading around $1.10 per share: What’s Next? - The DBT News

Oct 11, 2024
pulisher
Oct 11, 2024

Tempest Therapeutics Inc [NASDAQ: TPST] Sees Decrease in Stock Value - Knox Daily

Oct 11, 2024
pulisher
Oct 11, 2024

Tempest Therapeutics shares retain Buy rating post Roche deal - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Market Momentum: Tempest Therapeutics Inc (TPST) Registers a -18.52 Decrease, Closing at 1.10 - The Dwinnex

Oct 11, 2024
pulisher
Oct 11, 2024

Tempest Therapeutics shares retain Buy rating post Roche deal By Investing.com - Investing.com UK

Oct 11, 2024
pulisher
Oct 10, 2024

Tempest Therapeutics Inc (TPST) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

TPST’s price-to-free cash flow ratio: What it means for investors - US Post News

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study - XM

Oct 10, 2024
pulisher
Oct 10, 2024

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell - Marketscreener.com

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest stock gains on Roche collaboration (NASDAQ:TPST) - Seeking Alpha

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Therapeutics partners with Roche on cancer trial - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - ForexTV.com

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Therapeutics, Inc Enters into Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd. to Which Roche Will Supply Roche?S Atezolizumab - Marketscreener.com

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Extends Limited Duration Stockholder Rights Plan - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Tempest Announces Agreement with Roche to Support - GlobeNewswire

Oct 10, 2024
pulisher
Oct 04, 2024

Healthy Upside Potential: Tempest Therapeutics Inc (TPST) - SETE News

Oct 04, 2024
pulisher
Oct 03, 2024

TPST Shares Experience Surge in Value - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

How to interpret Tempest Therapeutics Inc (TPST)’s stock chart patterns - US Post News

Oct 03, 2024
pulisher
Sep 24, 2024

Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk

Sep 23, 2024
pulisher
Sep 23, 2024

A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com

Sep 23, 2024
pulisher
Sep 23, 2024

See Who's Joining Sigourney Weaver in West End The Tempest - Playbill

Sep 23, 2024
pulisher
Sep 23, 2024

Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat

Sep 23, 2024

Tempest Therapeutics Inc (TPST) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
大文字化:     |  ボリューム (24 時間):